Moderna Balance Sheet Health
Financial Health criteria checks 6/6
Moderna has a total shareholder equity of $11.9B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.8B and $3.9B respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.87b |
| Equity | US$11.93b |
| Total liabilities | US$3.88b |
| Total assets | US$15.80b |
Recent financial health updates
No updates
Recent updates
Moderna: Assessing The Impact Of GSK's Patent Lawsuit
Oct 22The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%
Oct 11
Moderna: Still Bullish View
Sep 20Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling
Sep 12Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
Aug 26Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop
Aug 18Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results
Aug 03Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
Jul 30Moderna: Really Strong Competition
Jun 30Moment Of Truth Approaches For Moderna's RSV Vaccine
Jun 18What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You
Jun 06Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor
May 23Moderna Q1: A Promising Pipeline Is Undervalued
May 15We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed
Apr 30Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22Moderna: Considering The Cancer Vaccine Angle
Apr 11Moderna Continues To Build A Pipeline
Apr 03Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play
Mar 27Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27Moderna: Counting On Pipeline Too Much
Feb 23Financial Position Analysis
Short Term Liabilities: MRNA's short term assets ($9.7B) exceed its short term liabilities ($2.2B).
Long Term Liabilities: MRNA's short term assets ($9.7B) exceed its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: MRNA is debt free.
Reducing Debt: MRNA had no debt 5 years ago.
Debt Coverage: MRNA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MRNA has no debt, therefore coverage of interest payments is not a concern.